In a clinical randomized controlled study, omalizumab α significantly reduced the incidence of exacerbations in ABPA patients, as well as serum total IgE and FeNO levels (Voskamp et al., 2015). Here, IGHE is linked to allergic bronchopulmonary aspergillosis.